ArticleLeukemia2024
Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolution.
Open access · hybridAbstract read
In one paragraph
Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 12 citations in OpenAlex.
- Targeting the tumor microenvironment: a new strategy for natural products in breast cancer therapy.Natural products and bioprospecting · 2026Review
- Article
- Unraveling the many faces of angioimmunoblastic T-cell lymphoma: clinical, pathological, and molecular heterogeneity.Annals of hematology · 2026Review
- Multi-omics analysis unveils tumor heterogeneity and immunotherapy predictive model in breast cancer for precision medicine and early detection.Neoplasia (New York, N.Y.) · 2026Article
- PLS3 Is a Prognostic Biomarker and Correlates with Immune Infiltrates in Head and Neck Squamous Cell Carcinoma.Cancers · 2025Article
- T-cell receptor architecture and clonal tiding provide insight into the transformation trajectory of peripheral T-cell lymphomas.Haematologica · 2025Article
- Oligoclonality of TRBC1 and TRBC2 in T cell lymphomas as mechanism of primary resistance to TRBC-directed CAR T cell therapies.Nature communications · 2025Article
- Reply to: Oligoclonality of TRBC1 and TRBC2 in T cell lymphomas as mechanism of primary resistance to TRBC-directed CAR T cell therapies.Nature communications · 2025Article
- Igniting Cold Tumors: Multi-Omics-Driven Strategies to Overcome Immune Evasion and Restore Immune Surveillance.Oncology research · 2025Review
- Rewiring tumor visibility: The immunopeptidome as a dynamic interface between antigen processing, microenvironmental stress, and immune recognition.Frontiers in oncology · 2025Review
- Clones in blood and stratified epithelial cells, and their drivers.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2025Review
- Challenges in defining the immune microenvironment in T-cell lymphoma.Haematologica · 2025Article
- CPRCSdb: A comprehensive phenotype-associated single-cell transcriptomic database for human cancer.Computational and structural biotechnology journal · 2025Article
- VISTAFrontiers in immunology · 2025Article
- Single-cell transcriptomic and spatial analysis reveal the immunosuppressive microenvironment in relapsed/refractory angioimmunoblastic T-cell lymphoma.Blood cancer journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 9 institutions in 3 countries.
Sakurako SumaDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.ORCID http://orcid.org/0000-0003-2491-3798
Yasuhito SueharaDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Manabu FujisawaDepartment of Hematology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Yoshiaki AbeDepartment of Hematology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.ORCID http://orcid.org/0000-0002-1021-7911
Keiichiro HattoriDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Kenichi MakishimaDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.ORCID http://orcid.org/0000-0002-5808-816X
Tatsuhiro SakamotoDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.ORCID http://orcid.org/0000-0001-6852-0721
Aya SawaDepartment of Breast-Thyroid-Endocrine Surgery, University of Tsukuba Hospital, Tsukuba, Japan.
Hiroko BandoDepartment of Breast-Thyroid-Endocrine Surgery, University of Tsukuba Hospital, Tsukuba, Japan.
Daisuke KajiDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Takeshi SugioDepartment of Medicine, Division of Oncology, Stanford University, Stanford, CA, USA.
Koji KatoDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Koichi AkashiDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Kosei MatsueDivision of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan.
Joaquim CarrerasDepartment of Pathology, Tokai University School of Medicine, Isehara, Japan.ORCID http://orcid.org/0000-0002-6129-8299
Naoya NakamuraDepartment of Pathology, Tokai University School of Medicine, Isehara, Japan.
Ayako SuzukiDepartment of Computational Biology and Medical Sciences, the University of Tokyo, Kashiwa, Japan.
Yutaka SuzukiDepartment of Computational Biology and Medical Sciences, the University of Tokyo, Kashiwa, Japan.
Ken ItoOncology Business Unit, Eisai Co., Ltd., Tsukuba, Japan.
Hiroyuki ShiibaOncology Department, Medical Head Quarters, Eisai Co., Ltd., Tokyo, Japan.
Shigeru ChibaDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Mamiko Sakata-YanagimotoDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan. sakatama@md.tsukuba.ac.jp.ORCID http://orcid.org/0000-0001-7310-8045
University of Tsukuba · JPUniversity of Tsukuba Hospital · JPEisai (Japan) · JPKyushu University · JPThe University of Tokyo · JPTokai University · JPKameda Medical Center · JPStanford University · USToranomon Hospital · JP
Funding
MEXT | Japan Society for the Promotion of Science (JSPS) JP20J20851MEXT | Japan Society for the Promotion of Science (JSPS) JP21K16261MEXT | Japan Society for the Promotion of Science (JSPS) JP22K19451, JP21H02945MEXT | Japan Society for the Promotion of Science (JSPS) JP23K15293MEXT | Japan Society for the Promotion of Science (JSPS) JP23K15316MEXT | Japan Society for the Promotion of Science (JSPS) JP23K15317
Abstract
T follicular helper (T
Indexed as
Lymphoma, FollicularT-Lymphocytes, Helper-InducerBiomarkers, TumorCD8-Positive T-LymphocytesDNA Copy Number VariationsHumansKiller Cells, NaturalPhenotypeTumor MicroenvironmentBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.